相关实验视频

Updated: Jan 17, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

桥梁安全性和有效性;新辅助化疗在接受瘤性乳腺手术治疗的患者中具有稳定的并发症率

Nagm Eldin Abu Elnga¹, Summar El-Morshidy², Mohamed K Safina³

¹General Surgery Department, Faculty of Medicine, Assiut University, Asyut, Egypt.

World journal of surgery

|September 19, 2025

概括

新辅助化疗 (NACT) 不会增加瘤性乳腺外科手术 (OBCS) 的术后并发症. 这一发现支持NACT对接受乳腺保护手术的乳腺癌患者的安全性.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
乳腺癌研究研究乳腺癌研究

背景情况:

瘤塑性乳腺手术技术使新辅助化疗 (NACT) 后的乳腺保护手术成为可能.
人们担心,在瘤塑性乳腺手术中,NACT后术后并发症的潜在增加.
这项研究调查了NACT对乳腺癌患者进行瘤整形手术后术并发症的影响,而不是前置手术.

研究的目的:

评估新辅助化疗 (NACT) 是否会增加乳腺癌患者进行瘤乳腺保护手术 (OBCS) 的术后并发症.
为了比较接受NACT和接受前置手术的患者之间的并发症率.

主要方法:

在阿苏特大学医院接受OBCS治疗的306名患者的回顾性分析 (2018年1月 - 2022年12月).
接受NACT和接受前期手术的患者之间的人口特征和术后并发症的比较.
风险因素和特定并发症的统计分析,包括伤口缺口,感染,血清瘤,缺血,脂肪缩,痕,乳腺炎和感觉丧失.

主要成果:

该研究包括306名患者:210人接受了NACT,96人接受了前置手术.
在NACT和前期手术组之间没有发现显著的人口差异.
术后并发症的发生率在两组中都相似,在特定并发症 (如伤口缺口,感染,血清瘤或NAC缺血症) 中没有显著差异.

结论:

新辅助化疗 (NACT) 在瘤塑性乳腺保护手术 (OBCS) 中不会提高并发症率.
这些发现支持在接受OBCS的乳腺癌患者中使用NACT的安全性和可行性.
这些结果可以为治疗计划和患者咨询提供有关NACT和瘤塑性手术的信息.

关键词:

乳腺癌乳腺癌乳腺癌新辅助性化疗是一种新辅助性化疗.瘤塑性乳房保护手术术后并发症术后并发症外科手术的结果.

更多相关视频

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...